Sprint (S) Stock Is Down Today After Analyst Downgrade

NEW YORK (TheStreet) -- Shares of Sprint (S) were falling 5.6% to $4.31 Wednesday following a downgrade from Oppenheimer and concerns about a mobile price war.

In a note to investors analyst firm Oppenheimer downgraded Sprint to "underperform" from "perform" due to recent competition and higher spectrum costs in the AWS-3 auction.

"We believe Sprint will be the most negatively impacted by competitive responses, and we think the stock is overvalued after factoring in $8B in expenditures for the broadcast spectrum auctions," analysts Timothy Horan and Jonathan Michaels wrote. "Sprint is now trading at 8.8x our 2016E EBITDA estimate, which is nearly a 2x premium to the carriers, and not justified given negative FCF. We believe additional share issuances are on the horizon and will cause further equity dilution."

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Shares of all four major U.S. wireless carriers started to decline after Verizon (VZ) warned on Monday that it would see lower profits in the fourth quarter due to promotions offered to compete against lower prices from Sprint, T-Mobile (TMUS) , and AT&T (T) .

S Chart S data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug